News coverage about Oncobiologics (NASDAQ:ONS) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Oncobiologics earned a news impact score of 0.17 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.9044894575486 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of research analysts have weighed in on ONS shares. Barclays downgraded Oncobiologics from an “overweight” rating to an “equal weight” rating in a report on Monday, January 29th. ValuEngine raised Oncobiologics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $9.00.
Oncobiologics (NASDAQ ONS) traded up $0.01 during mid-day trading on Tuesday, reaching $1.20. The company’s stock had a trading volume of 7,100 shares, compared to its average volume of 53,628. Oncobiologics has a 52 week low of $0.78 and a 52 week high of $3.77. The company has a debt-to-equity ratio of -0.40, a quick ratio of 0.14 and a current ratio of 0.14.
In other Oncobiologics news, CEO Pankaj Mohan sold 114,677 shares of the company’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $1.17, for a total value of $134,172.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Lawrence A. Kenyon sold 26,165 shares of the company’s stock in a transaction dated Friday, December 22nd. The stock was sold at an average price of $1.13, for a total value of $29,566.45. The disclosure for this sale can be found here. In the last three months, insiders sold 284,508 shares of company stock worth $328,317. 33.50% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Oncobiologics (ONS) Share Price” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/13/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-oncobiologics-ons-share-price.html.
Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.